Chao Wan

Chao Wan

Auto-generated profile, based on publicly available information

Chao Wan

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
CWChao Wan
Chao Wan
YSYajie Sun
Yajie Sun
YTYu Tian
Yu Tian
LLLisen Lu
Lisen Lu
XDXiaomeng Dai
Xiaomeng Dai
KYKunyu Yang
Kunyu Yang
By mimicking the RIBE machinery, we provided an indirect radiotherapy approach based on RT-MP for eradication of MPE in mice.

8 December 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
JMJingshu Meng
Jingshu Meng
YLYan Li
Yan Li
CWChao Wan
Chao Wan
YSYajie Sun
Yajie Sun
XDXiaomeng Dai
Xiaomeng Dai
KYKunyu Yang
Kunyu Yang
Cancer cell radioresistance is the primary cause of the decreased curability of non–small cell lung cancer (NSCLC) observed in patients receiving definitive radiotherapy (RT). Following RT, a set of microenvironmental stress responses is triggered, including cell senescence. However, cell senescence is often ignored in designing effective strategies to resolve cancer cell radioresistance. Herein, we identify the senescence-like characteristics of cancer-associated fibroblasts (CAFs) after RT and clarify the formidable ability of senescence-like CAFs in promoting NSCLC cell proliferation and radioresistance through the JAK/STAT pathway. Specific induction of senescence-like CAF apoptosis using FOXO4-DRI, a FOXO4-p53–interfering peptide, resulted in remarkable effects on radiosensitizing NSCLC cells in vitro and in vivo. In addition, in this study, we also uncovered an obvious therapeutic effect of FOXO4-DRI on alleviating radiation-induced pulmonary fibrosis (RIPF) by targeting senescence-like fibroblasts in vivo. In conclusion, by targeting senescence, we offer a strategy that simultaneously decreases radioresistance of NSCLC and the incidence of RIPF.

23 February 2022 in Translational Oncology
Verified
Journal Article
Open access
DZDanyi Zhai
Danyi Zhai
DADandan An
Dandan An
CWChao Wan
Chao Wan
KYKunyu Yang
Kunyu Yang
• Radiotherapy has bright side as well as dark side on immune system. • Radiotherapy does not always synergize with immunotherapy. • Fully consideration of radiotherapy regimens and schedules is needed to maximize the immunostimulatory effect of radioimmunotherapy. • Application of new techniques may be a sharp weapon in improving the effect of radioimmunotherapy.

1 January 2024 in Theranostics
Verified
Journal Article
Open access
PDF file
YDYue Deng
Yue Deng
QCQinyan Chen
Qinyan Chen
XYXiao Yang
Xiao Yang
YSYajie Sun
Yajie Sun
BZBin Zhang
Bin Zhang
KYKunyu Yang
Kunyu Yang
Background: The role of senescent cells in the tumor microenvironment (TME) is usually bilateral, and diverse therapeutic approaches, such as radiotherapy and chemotherapy, can induce cellular senescence. Cellular interactions are widespread in the TME, and tumor cells reprogram immune cells metabolically by producing metabolites. However, how senescent cells remodel the metabolism of TME remains unclear. This study aimed to explore precise targets to enhance senescent cells-induced anti-tumor immunity from a metabolic perspective.

29 January 2024 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZZZhiyuan Zhou
Zhiyuan Zhou
BZBin Zhang
Bin Zhang
YDYue Deng
Yue Deng
SDSuke Deng
Suke Deng
JLJie Li
Jie Li
KYKunyu Yang
Kunyu Yang
Background: The development of radioresistance seriously hinders the efficacy of radiotherapy in lung cancer. However, the underlying mechanisms by which radioresistance occurs are still incompletely understood. The N6-Methyladenosine (m6A) modification of RNA is involved in cancer progression, but its role in lung cancer radioresistance remains elusive. This study aimed to identify m6A regulators involved in lung cancer radiosensitivity and further explore the underlying mechanisms to identify therapeutic targets to overcome lung cancer radioresistance. Methods: Bioinformatic mining was used to identify the m6A regulator IGF2BP2 involved in lung cancer radiosensitivity. Transcriptome sequencing was used to explore the downstream factors. Clonogenic survival assays, neutral comet assays, Rad51 foci formation assays, and Annexin V/propidium iodide assays were used to determine the significance of FBW7/IGF2BP2/SLC7A5 axis in lung cancer radioresistance. Chromatin immunoprecipitation (ChIP)-qPCR analyses, RNA immunoprecipitation (RIP) and methylated RNA immunoprecipitation (MeRIP)-qPCR analyses, RNA pull-down analyses, co-immunoprecipitation analyses, and ubiquitination assays were used to determine the feedback loop between IGF2BP2 and SLC7A5 and the regulatory effect of FBW7/GSK3β on IGF2BP2. Mice models and tissue microarrays were used to verify the effects in vivo. Results: We identified IGF2BP2, an m6A “reader”, that is overexpressed in lung cancer and facilitates radioresistance. We showed that inhibition of IGF2BP2 impairs radioresistance in lung cancer both in vitro and in vivo. Furthermore, we found that IGF2BP2 enhances the stability and translation of SLC7A5 mRNA through m6A modification, resulting in enhanced SLC7A5-mediated transport of methionine to produce S-adenosylmethionine. This feeds back upon the IGF2BP2 promoter region by further increasing the trimethyl modification at lysine 4 of histone H3 (H3K4me3) level to upregulate IGF2BP2 expression. We demonstrated that this positive feedback loop between IGF2BP2 and SLC7A5 promotes lung cancer radioresistance through the AKT/mTOR pathway. Moreover, we found that the ubiquitin ligase FBW7 functions with GSK3β kinase to recognize and degrade IGF2BP2. Conclusions: Collectively, our study revealed that the m6A “reader” IGF2BP2 promotes lung cancer radioresistance by forming a positive feedback loop with SLC7A5, suggesting that IGF2BP2 may be a potential therapeutic target to control radioresistance in lung cancer.

30 October 2023 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Open access
JLJie Li
Jie Li
MCMengjie Che
Mengjie Che
BZBin Zhang
Bin Zhang
KZKewei Zhao
Kewei Zhao
CWChao Wan
Chao Wan
KYKunyu Yang
Kunyu Yang
This review summarizes emerging evidence that the neuroendocrine system is involved in the regulation of the tumor immune microenvironment (TIME) to influence cancer progression. The basis of the interaction between the neuroendocrine system and cancer is usually achieved by the infiltration of nerve fibers into the tumor tissue, which is called neurogenesis; the migration of cancer cells toward nerve fibers, which is called perineural invasion (PNI), and the neurotransmitters. In addition to the traditional role of neurotransmitters in neural communications, neurotransmitters are increasingly recognized as mediators of crosstalk between the nervous system, cancer cells, and the immune system.Recent studies have revealed that not only nerve fibers but also cancer cells and immune cells within the TIME can secrete neurotransmitters, exerting influence on both neurons and themselves. Furthermore, immune cells infiltrating the tumor environment have been found to express a wide array of neurotransmitter receptors. Hence, targeting these neurotransmitter receptors may promote the activity of immune cells in the tumor microenvironment and exert anti-tumor immunity. Herein, we discuss the crosstalk between the neuroendocrine system and tumor-infiltrating immune cells, which may provide feasible cancer immunotherapy options.